Legence: Expecting A Bounce Back In 2027

Legence (LGN) received a Strong Buy rating as it benefits from Bowers Group integration and robust earnings growth, even with margin pressure from Bowers. The company raised guidance to target $450M of adjusted EBITDA in 2026 and trades at 9.39x EV/EBITDA, suggesting valuation support. Private equity selling—Blackstone cutting its stake from 72% to 47%—has weighed on sentiment, but the update largely reinforces the growth and guidance outlook.

Analysis

The key market mechanism is not the headline growth rate; it is whether integration can convert revenue scale into durable margin expansion faster than the sponsor overhang suppresses multiple. If management is already lifting forward earnings while absorbing acquisition drag, that usually signals the business is taking share in a fragmented niche and can negotiate better procurement terms, but the equity will not re-rate until the market sees sequential margin proof rather than promises.

Second-order winners are smaller private competitors and any public peers that lack acquisition-driven scale, because LGN can use a broader service footprint to bid more aggressively on bundled contracts. The likely loser is not BX's franchise economics; it is LGN's near-term stock price if additional distribution keeps creating a technical supply overhang. That said, sponsor selling is often a liquidity event, not a fundamental warning, so the market may be over-penalizing the stock if the business continues to execute.

The immediate catalyst window is the next 1-3 months: earnings, margin progression, and any further secondary blocks. Over 6-18 months, the setup works only if integration costs roll off and free cash flow converts cleanly; if not, a low-multiple story can stay low multiple. What would falsify the thesis is any reset in the 2026 earnings path, a widening gap between adjusted EBITDA and cash earnings, or evidence that the acquisition is diluting rather than accretive on a run-rate basis.

Key Decisions for Investors

• Long LGN on weakness over the next 1-3 months; treat the sponsor selling as a technical entry opportunity if the stock remains below peer valuation despite intact guidance.
• Use a defined-risk LGN call spread for 6-12 months if liquidity allows; the catalyst is multiple expansion once integration proof points show up, not immediate momentum.
• Pair trade: long LGN / short BX tactically only if additional secondary sales hit the tape and pressure the stock; cover the short if BX stops distributing or LGN prints cleaner margins.
• Set a hard alert on the next quarterly report: if adjusted margin does not improve sequentially or free cash flow conversion disappoints, de-risk immediately.
• Do not chase BX as a long based on monetization headlines; the better expression is to own the operating story and wait for the overhang to clear.